Trials (Oct 2022)

A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)

  • I. W. J. M. van Goor,
  • L. A. Daamen,
  • M. G. Besselink,
  • A. M. E. Bruynzeel,
  • O. R. Busch,
  • G. A. Cirkel,
  • B. Groot Koerkamp,
  • N. Haj Mohammed,
  • H. D. Heerkens,
  • H. W. M. van Laarhoven,
  • G. J. Meijer,
  • J. Nuyttens,
  • H. C. van Santvoort,
  • G. van Tienhoven,
  • H. M. Verkooijen,
  • J. W. Wilmink,
  • I. Q. Molenaar,
  • M. P. W. Intven,
  • for the Dutch Pancreatic Cancer Group

DOI
https://doi.org/10.1186/s13063-022-06829-1
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20–30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved local control in these patients, potentially having a beneficial effect on both survival and quality of life. The “nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy” (ARCADE) will investigate the value of SBRT in addition to standard of care in patients with isolated local PDAC recurrence compared to standard of care alone, regarding both survival and quality of life outcomes. Methods The ARCADE trial is nested within a prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the ‘Trials within Cohorts’ design. All PACAP participants with isolated local PDAC recurrence after primary resection who provided informed consent for being randomized in future studies are eligible. Patients will be randomized for local therapy (5 fractions of 8 Gy SBRT) in addition to standard of care or standard of care alone. In total, 174 patients will be included. The main study endpoint is survival after recurrence. The most important secondary endpoint is quality of life. Discussion It is hypothesized that additional SBRT, compared to standard of care alone, improves survival and quality of life in patients with isolated local recurrence after PDAC resection. Trial registration ClinicalTrials.gov registration NCT04881487 . Registered on May 11, 2021.

Keywords